Trials / Completed
CompletedNCT01097018
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 468 (actual)
- Sponsor
- AEterna Zentaris · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The trial will compare the overall survival of perifosine plus capecitabine to placebo plus capecitabine in patients with refractory advanced colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine | 1000 mg/m2 BID/ Days 1-14 |
| DRUG | Perifosine | 50 mg daily x 21 days |
| DRUG | Placebo | 1 pill daily x 21 days |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2010-04-01
- Last updated
- 2013-07-02
Locations
65 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01097018. Inclusion in this directory is not an endorsement.